Abstract
Aim:  There is currently no well‐accepted therapy for central nervous system Langerhans cell histiocytosis (CNS‐LCH), a neuroinflammatory disease clinically characterized by often progressive, neurological symptoms including ataxia, dysarthria, dysphagia, hypertonicity, intellectual impairment and behavioural abnormalities. We applied immunomodulative/anti‐inflammatory treatment on a patient with progressive CNS‐LCH disease.Method:  Intravenous immunoglobulin (IVIG) was administered monthly for 15 years to a patient with severe, image‐verified neurodegenerative CNS‐LCH.Results:  During the IVIG treatment, the neurological deterioration initially appeared to be haltered, but over time there was still some deterioration.Conclusions:  IVIG may be beneficial in partly haltering CNS‐LCH neurodegeneration, but further studies are needed.

This publication has 15 references indexed in Scilit: